Ann: Significant Immunological Outcomes in BIT225 HIV-1 Trial, page-170

For those new here. here is my take.

BIT has had a lot of promise for a very long time but tended to suffer from "lackoffundsitis". BIT225 has the very real potential (and not just as a co-medication). BIT have a game changer IMHO, but have had to be very careful with their money and it has taken longer than ideal to get to this stage, which further complicates the whole fund raising issue.

Its always hard (in Australia) to get these things off the ground as we just don't support the junior biomed sector.

At either measure, it is getting hard to ignore BIT and BIT225 after the last few days. I imagine we will see further information about the study, which should help project it to the next level.

Hopefully management take the opportunity to do some long and overdue PR. You now have the stage, make the most of it.

Good luck to holders. This at 9c is still cheap for the long term, and the risk/reward scenario is still looking good IMHO.